New Vaccine Study Offers Hope for Cancer Patients
A recent study indicates that a familiar vaccine may play a role in battling cancer. Researchers discovered that cancer patients receiving the mRNA COVID-19 vaccine within 100 days of starting immune checkpoint therapy saw significantly improved survival rates.
Conducted by experts from the University of Florida and the University of Texas MD Anderson Cancer Center, the study analyzed data from over 1,000 patients with Stage 3 and 4 non-small cell lung cancer and metastatic melanoma treated at MD Anderson from 2019 to 2023.
All patients were treated with immune checkpoint inhibitors, which are immunotherapy drugs designed to help the immune system recognize and destroy cancer cells. Some of these patients received the mRNA COVID-19 vaccine shortly after beginning their immunotherapy, while others did not.
The results were promising. Patients who received both the vaccine and immunotherapy had an average survival of 37.3 months, nearly double the 20.6 months seen in those who only had the immunotherapy.
The most significant benefits emerged in patients with so-called “cold” tumors, which usually resist immunotherapy. In these cases, the addition of the COVID-19 vaccine nearly quintupled the three-year overall survival rate.
The data collected so far may not capture the full effects of the vaccine, as some patients were still alive at the time of reporting. The researchers also conducted experiments on mice, finding that tumors became more responsive to treatment when the mice received both immunotherapy and an mRNA vaccine targeting the COVID-19 spike protein.
While findings from non-mRNA vaccines for flu and pneumonia did not yield similar benefits, the researchers believe this could have a significant impact on cancer treatment. Senior researcher Dr. Elias Sayour emphasizes that this could transform oncological care.
Although the study is observational, the researchers stress the importance of further clinical trials to validate their findings. Dr. Duane Mitchell noted that proving these results in larger, randomized studies is crucial.
The researchers are set to launch a large clinical trial through the OneFlorida+ Clinical Research Network, which includes hospitals and health centers across several states. They hope to develop a “universal, off-the-shelf” vaccine that could enhance the immune response in cancer patients, potentially increasing survival across various types of cancer.
The study received support from the National Institutes of Health, the National Cancer Institute, and several other organizations.
